000136802 001__ 136802
000136802 005__ 20240229105100.0
000136802 0247_ $$2doi$$a10.1007/s00520-018-4095-3
000136802 0247_ $$2pmid$$apmid:29445858
000136802 0247_ $$2ISSN$$a0941-4355
000136802 0247_ $$2ISSN$$a1433-7339
000136802 0247_ $$2altmetric$$aaltmetric:33288089
000136802 037__ $$aDKFZ-2018-01240
000136802 041__ $$aeng
000136802 082__ $$a610
000136802 1001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b0$$eFirst author$$udkfz
000136802 245__ $$aL-Thyroxine intake as a potential risk factor for the development of fatigue in breast cancer patients undergoing chemotherapy.
000136802 260__ $$aBerlin$$bSpringer$$c2018
000136802 3367_ $$2DRIVER$$aarticle
000136802 3367_ $$2DataCite$$aOutput Types/Journal article
000136802 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1536302120_11752
000136802 3367_ $$2BibTeX$$aARTICLE
000136802 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136802 3367_ $$00$$2EndNote$$aJournal Article
000136802 520__ $$aL-Thyroxine is one of the most commonly prescribed drugs and accordingly used by many breast cancer patients with thyroid disorders. Hence, potential interactions of chemotherapy with L-thyroxine, possibly contributing to fatigue, would be of high clinical relevance. Therefore, we investigated fatigue and underlying pathways in L-thyroxine-using breast cancer patients during chemotherapy.Thyroid-stimulating hormone (TSH), L-triiodothyronine (T3), and diurnal salivary cortisol patterns were analyzed in breast cancer patients in the beginning and at the end of adjuvant chemotherapy within the control group (n = 41) of a randomized exercise intervention trial. Additionally, relationships in the exercising group (n = 45) as well as in healthy women (n = 25) were explored. Regression and mediation analyses were performed.L-Thyroxine use was significantly associated with lower TSH (median = 0.33 mU/l, interquartile range = (0.15-0.48)), whereas patients not using L-thyroxine had TSH comparable to healthy women (0.51 mU/l (0.37-0.74)). T3 significantly declined during chemotherapy in L-thyroxine users but not in non-users. However, the group difference failed statistical significance. L-Thyroxine treatment was significantly associated with increased physical fatigue during chemotherapy (p = 0.004) in the non-exercising group. This association appeared to be partly mediated by TSH. Further, TSH appeared to affect fatigue partly via increased cortisol levels. In the exercise group, there was no significant association between L-thyroxine and fatigue.L-Thyroxine treatment during chemotherapy might result in hormonal dysregulations that can contribute to increased physical fatigue. Therefore, breast cancer patients on L-thyroxine treatment may need special monitoring of their thyroid levels and of fatigue during chemotherapy and should be encouraged to exercise.ClinicalTrials.gov NCT01106820.
000136802 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000136802 588__ $$aDataset connected to CrossRef, PubMed,
000136802 7001_ $$aWiskemann, Joachim$$b1
000136802 7001_ $$0P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aJohnson, Theron Scot$$b2$$udkfz
000136802 7001_ $$aHabermann, Nina$$b3
000136802 7001_ $$aSchneeweiss, Andreas$$b4
000136802 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b5$$eLast author$$udkfz
000136802 773__ $$0PERI:(DE-600)1463166-0$$a10.1007/s00520-018-4095-3$$gVol. 26, no. 8, p. 2561 - 2569$$n8$$p2561 - 2569$$tSupportive care in cancer$$v26$$x1433-7339$$y2018
000136802 909CO $$ooai:inrepo02.dkfz.de:136802$$pVDB
000136802 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000136802 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000136802 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000136802 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000136802 9141_ $$y2018
000136802 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000136802 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136802 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136802 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136802 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSUPPORT CARE CANCER : 2015
000136802 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000136802 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000136802 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136802 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136802 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136802 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136802 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000136802 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000136802 9201_ $$0I:(DE-He78)G210-20160331$$kG210$$lBewegung, Präventionsforschung und Krebs$$x0
000136802 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x1
000136802 980__ $$ajournal
000136802 980__ $$aVDB
000136802 980__ $$aI:(DE-He78)G210-20160331
000136802 980__ $$aI:(DE-He78)C020-20160331
000136802 980__ $$aUNRESTRICTED